Antibody Drug Conjugates Market Size, Share, Growth Insights and Report 2024-2031 | AstraZeneca, Gilead Sciences Inc, Seagen Inc

Global Antibody Drug Conjugates Market size reached USD 5,032.8 million in 2022 and is projected to witness lucrative growth by reaching up to USD 16,594.6 million by 2030. The market is exhibiting at a CAGR of 16.6% during the forecast period (2024-2031)

DataM Intelligence has published a new research report on "Antibody Drug Conjugate Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Segmentation, CAGR, business revenue competitive positioning of key companies, investigating elements such as product offerings, pricing strategies, financial performance, product portfolios, growth initiatives, and geographical reach. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Get a Free Sample Research PDF - https://www.datamintelligence.com/download-sample/antibody-drug-conjugates-market

Antibody Drug Conjugates (ADCs) are targeted cancer therapies that combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs. The antibody in an ADC specifically binds to cancer cell surface antigens, allowing the attached cytotoxic drug to be delivered directly to the tumor cells. Once the ADC binds to the cancer cell, it is internalized, and the drug is released to destroy the cell. This targeted approach aims to minimize damage to healthy cells while maximizing the therapeutic effect on cancer cells, making ADCs a promising treatment option for various types of cancer.

Key Developments:

In May 2023, Sony Corporation, a technology company and Astellas Pharma Inc., a pharmaceutical company, announced that they entered into a collaborative research agreement to discover a novel Antibody-Drug Conjugate (ADC) platform in oncology based on Sony's unique polymeric material, KIRAVIA ADC is expected to selectively deliver anti-cancer drugs to target cells, thereby increasing efficacy and reducing side effects caused by anti-cancer drugs attacking normal cells.
In May 2023, Sutro Biopharma, Inc., a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), reported its financial results for the first quarter of 2023, its recent business highlights, and a preview of select anticipated milestones.
Research Process:

Both primary and secondary data sources have been used in the global Antibody Drug Conjugate Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

List of the Key Players in the Antibody Drug Conjugate Market: Takeda Pharmaceutical Company Ltd., Hoffmann-La Roche Ltd., Pfizer Inc., AstraZeneca, Gilead Sciences Inc., Seagen Inc., Astellas Pharma, Daiichi Sankyo Company Ltd., GlaxoSmithKline Plc, and ADC Therapeutics.

Segment Covered in the Antibody Drug Conjugate Market:

By Application (Breast cancer, Blood cancer, Skin cancer, Lung cancer, Others)

By Technology (Non-cleavable linker, Cleavable linker, Linker less)

Regional Analysis:

The global Antibody Drug Conjugate Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/antibody-drug-conjugates-market

Regional Analysis:

The global Antibody Drug Conjugate Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa. The report offers detailed insight into new product launches, new technology evolutions, innovative services, and ongoing R&D. The report discusses a qualitative and quantitative market analysis, including PEST analysis, SWOT analysis, and Porter's five force analysis. The Antibody Drug Conjugate Market report also provides fundamental details such as raw material sources, distribution networks, methodologies, production capacities, industry supply chain, and product specifications.

**The full version of the report includes an in-depth analysis of emerging players and startups, which will provide valuable insights into the evolving market landscape and key strategies being adopted**

Chapter Outline:

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: key insights, key emerging trends, etc.

Chapter 3: Manufacturers competitive analysis, detailed analysis of Antibody Drug Conjugate manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 5 & 6: Revenue of Antibody Drug Conjugate in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: The main points and conclusions of the report.

Have any Query? Talk to our Expert @ https://www.datamintelligence.com/enquiry/antibody-drug-conjugates-market

Frequently Asked Questions

Q1) How Big is the Antibody Drug Conjugate Market?

A) Global Antibody Drug Conjugates Market size reached USD 5,032.8 million in 2022 and is projected to witness lucrative growth by reaching up to USD 16,594.6 million by 2030

Q2) Who are the key players of Antibody Drug Conjugate Market?

A) AstraZeneca, Gilead Sciences Inc., Seagen Inc., Astellas Pharma, Daiichi Sankyo Company Ltd., GlaxoSmithKline Plc, and ADC Therapeutics.

Q3) What are the regions covered in this report?

A) The global Antibody Drug Conjugate Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa

4) What are the Segments Coverd in this report?

A) The Antibody Drug Conjugate market is segmented as By Application, By Technology

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.